Aptevo Therapeutics Inc. is a clinical-stage biotechnology company based in Seattle, WA, dedicated to developing innovative bispecific immunotherapies for cancer treatment, with a focus on improving outcomes and transforming the lives of cancer patients.
With a broad pipeline designed to target multiple mechanisms of action, Aptevo is at the forefront of advancing the science of immuno-oncology. Their lead candidate, APVO436, is specifically developed to combat Acute Myeloid Leukemia, demonstrating their commitment to developing meaningful therapeutics in the fight against cancer.
Generated from the website